Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes

Obstetrics and Gynecology

Volumn 117, Issue 1, 2011, Pages 75-83

  Lynch, Anne M ^a   Gibbs, Ronald S ^a   Murphy, James R ^a   Giclas, Patricia C ^a   Salmon, Jane E ^a   Holers, V Michael ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A;

ABORTION; ADULT; ARTICLE; COHORT ANALYSIS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PREECLAMPSIA; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; BIOLOGICAL MARKERS; COMPLEMENT C3A; FEMALE; HUMANS; LOGISTIC MODELS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PROSPECTIVE STUDIES;

EID: 78650768741     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181fc3afa     Document Type: Article

References (46)

1. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-66.
2. Sjöberg AP, Trouw LA, Blom AM. Complement activation and inhibition: a delicate balance. Trends Immunol 2009; 30: 83-90.
3. Holers VM. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev 2008;223:300-16.
4. Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007;171:715-27.
5. Pickering MC, Cook HT. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 2008;151:210-30.
6. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010;11:785-97.
7. Holmes CH, Simpson KL. Complement and pregnancy: new insights into the immunobiology of the fetomaternal relationship. Baillieres Clin Obstet Gynaecol 1992;6:439-60.
8. Lynch AM, Salmon JE. Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta 2010;31:561-7.
9. Caucheteux SM, Kanellopoulos-Langevin C, Ojcius DM. At the innate frontiers between mother and fetus: linking abortion with complement activation. Immunity 2003;18:169-72.
10. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195:211-20.
11. Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002;61(suppl 2): ii46-50.
12. Lynch AM, Murphy JR, Byers T, Gibbs RS, Neville MC, Giclas PC, et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol 2008;198:385.e1-9.
13. Lynch AM, Gibbs RS, Murphy JR, Byers T, Neville MC, Giclas PC, et al. Complement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am J Obstet Gynecol 2008;199:354.e1-8.
14. Fakhouri F, Roumenina L, Provot F, Sallee M, Caillard S, Couzi L, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010;21:859-67.
15. Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship TH, et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008;111:624-32.
16. Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP. Advances in understanding of pathogenesis of aHUS and HELLP. Br J Haematol 2008;143:336-48.
17. Lynch AM, Murphy JR, Gibbs RS, Levine RJ, Giclas PC, Salmon JE, et al. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG 2010; 117:456-62.
18. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99.
19. Goldstein SR. Embryonic death in early pregnancy: a new look at the first trimester. Obstet Gynecol 1994;84:294-7.
20. Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphos-pholipid antibodies and fetal death. Obstet Gynecol 1996;87: 489-93.
21. Resnick R, Creasy R. Intrauterine growth restriction. In: Creasy R, Resnik R, Iams J, Lockwood C, Moore T, editors. Creasy and Resnick's maternal-fetal medicine: principles and practice. Philadelphia (PA): WB Saunders; 2009. p. 635-50.
22. Lubchenco LO, Hansman C, Dressler M, Boyd E. Intrauterine growth as estimated from liveborn birth-weight data at 24 to 42 weeks of gestation. Pediatrics 1963;32:793-800.
23. Mercer BM. Preterm premature rupture of the membranes: diagnosis and management. Clin Perinatol 2004;31:765-82, vi.
24. Iams JD, Romero R, Creasy RK. Preterm labor and birth. In: Creasy RK, Resnik R, Iams JD, Lockwood CJ, Moore TR, editors. Creasy and Resnick's maternal-fetal medicine: principles and practice. 6th ed. Philadelphia (PA): WB Saunders; 2009. p. 545.
25. Dekker G, Robillard PY. Pre-eclampsia: is the immune mal-adaptation hypothesis still standing? An epidemiological update. J Reprod Immunol 2007;76:8-16.
26. Cordoba G, Schwartz L, Woloshin S, Bae H, Gotzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ 2010;341: c3920.
27. Derzsy Z, Prohaszka Z, Rigo J Jr, Fust G, Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 2010;47:1500-6.
28. Haeger M, Bengtson A, Karlsson K, Heideman M. Complement activation and anaphylatoxin (C3a and C5a) formation in preeclampsia and by amniotic fluid. Obstet Gynecol 1989;73: 551-6.
29. Romero R, Espinoza J, Goncalves LF, Kusanovic JP, Friel LA, Nien JK. Inflammation in preterm and term labour and delivery. Semin Fetal Neonatal Med 2006;11:317-26.
30. Soto E, Romero R, Richani K, Espinoza J, Nien JK, Chai-worapongsa T, et al. Anaphylatoxins in preterm and term labor. J Perinat Med 2005;33:306-13.
31. Soto E, Romero R, Richani K, Yoon BH, Chaiworapongsa T, Vaisbuch E, et al. Evidence for complement activation in the amniotic fluid of women with spontaneous preterm labor and intra-amniotic infection. J Matern Fetal Neonatal Med 2009; 22:983-92.
32. Vaisbuch E, Romero R, Erez O, Mazaki-Tovi S, Kusanovic JP, Soto E, et al. Activation of the alternative pathway of complement is a feature of pre-term parturition but not of spontaneous labor at term. Am J Reprod Immunol 2010;63:318-30.
33. Swierzko AS, Atkinson AP, Cedzynski M, Macdonald SL, Szala A, Domzalska-Popadiuk I, et al. Two factors of the lectin pathway of complement, l-ficolin and mannan-binding lectin, and their associations with prematurity, low birthweight and infections in a large cohort of Polish neonates. Mol Immunol 2009;46:551-8.
34. Elimian A, Figueroa R, Canterino J, Verma U, Aguero-Rosenfeld M, Tejani N. Amniotic fluid complement C3 as a marker of intra-amniotic infection. Obstet Gynecol 1998;92: 72-6.
35. Watts DH, Krohn MA, Hillier SL, Eschenbach DA. The association of occult amniotic fluid infection with gestational age and neonatal outcome among women in preterm labor. Obstet Gynecol 1992;79:351-7.
36. Romero R, Espinoza J, Goncalves LF, Kusanovic JP, Friel L, Hassan S. The role of inflammation and infection in preterm birth. Semin Reprod Med 2007;25:21-39.
37. Wilcox AJ, Weinberg CR, O'Connor JF, Baird DD, Schlatterer JP, Canfield RE, et al. Incidence of early loss of pregnancy. N Engl J Med 1988;319:189-94.
38. Andrews WW, Sibai BM, Thom EA, Dudley D, Ernest JM, McNellis D, et al. Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women. Obstet Gynecol 2003;101: 847-55.
39. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993;14:353-6.
40. Chaouat G. The Th1/Th2 paradigm: still important in pregnancy? Semin Immunopathol 2007;29:95-113.
41. Blank V, Hirsch E, Challis JR, Romero R, Lye SJ. Cytokine signaling, inflammation, innate immunity and preterm labour-a workshop report. Placenta 2008;29(suppl A):S102-4.
42. Lockwood CJ, Kuczynski E. Markers of risk for preterm delivery. J Perinat Med 1999;27:5-20.
43. Whitcomb BW, Schisterman EF, Klebanoff MA, Baumgarten M, Luo X, Chegini N. Circulating levels of cytokines during pregnancy: thrombopoietin is elevated in miscarriage. Fertil Steril 2008;89:1795-802.
44. Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response-a review. Placenta 2003;24(suppl A):S21-7.
45. Eunice Kennedy Shriver National Institute of Child Health and Human Development. EAGeR trial. Available at www. eagertrial.org/. Retrieved August 20, 2010.
46. Walport MJ. Complement. Second of two parts. N Engl J Med 2001;344:1140-4.